Gori Niccolò, Chiricozzi Andrea, Marsili Franco, Ferrucci Silvia Mariel, Amerio Paolo, Battarra Vincenzo, Campitiello Salvatore, Castelli Antonio, Congedo Maurizio, Corazza Monica, Cristaudo Antonio, Fabbrocini Gabriella, Girolomoni Giampiero, Malara Giovanna, Micali Giuseppe, Palazzo Giovanni, Parodi Aurora, Patrizi Annalisa, Pellacani Giovanni, Pigatto Paolo, Provenzano Eugenio, Quaglino Pietro, Romanelli Marco, Rossi Mariateresa, Savoia Paola, Peris Ketty
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, 00168 Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
J Clin Med. 2022 Sep 2;11(17):5204. doi: 10.3390/jcm11175204.
Atopic dermatitis (AD) is a common inflammatory skin disease often associated with a significant impairment in the quality of life of affected patients. The Italian Society of Dermatology and Venereology (SIDeMaST) planned a national information campaign, providing direct access to 27 dermatologic centers dedicated to the management of AD. The aim of this study aimed was to outline critical aspects related to AD in the general population. Overall, 643 adult subjects were included in this study, and in 44.2% (284/643) of cases, a diagnosis of AD was confirmed, whereas about 55% of subjects were affected by other pruritic cutaneous diseases. Higher intensity of pruritus and sleep disturbance, as well as an increased interference in sport, work, and social confidence was reported in the AD group compared to the non-AD group. In the AD subgroup, the mean duration of disease was of 15.3 years, with a mean eczema area and severity index (EASI) score of 11.2, and investigator global assessment (IGA) score of 1.9 and an itch numeric rating scale (NRS) of 6.9. Almost 32% of patients were untreated, either with topical or systemic agents, whereas 44.3% used routine topical compounds (topical corticosteroids and calcineurin inhibitors), and only 7.0% of patients were systemically treated. Only 2.8% of patients reported complete satisfaction with the treatment received for AD to date. This study reveals a profound unmet need in AD, showing a poorly managed and undertreated patient population despite a high reported burden of disease. This suggests the usefulness of information campaigns with the goal of improving patient awareness regarding AD and facilitating early diagnosis and access to dedicated healthcare institutions.
特应性皮炎(AD)是一种常见的炎症性皮肤病,常与受影响患者的生活质量显著受损相关。意大利皮肤病与性病学会(SIDeMaST)策划了一项全国性宣传活动,提供直接接入27个致力于AD管理的皮肤科中心的途径。本研究的目的是概述普通人群中与AD相关的关键方面。总体而言,本研究纳入了643名成年受试者,其中44.2%(284/643)的病例确诊为AD,而约55%的受试者患有其他瘙痒性皮肤病。与非AD组相比,AD组报告的瘙痒强度和睡眠障碍更高,以及对运动、工作和社交信心的干扰增加。在AD亚组中,疾病的平均持续时间为15.3年,湿疹面积和严重程度指数(EASI)平均评分为11.2,研究者整体评估(IGA)评分为1.9,瘙痒数字评定量表(NRS)为6.9。近32%的患者未接受局部或全身用药治疗,而44.3%的患者使用常规局部用药(局部皮质类固醇和钙调神经磷酸酶抑制剂),只有7.0%的患者接受了全身治疗。只有2.8%的患者表示对迄今为止接受的AD治疗完全满意。这项研究揭示了AD方面存在的巨大未满足需求,表明尽管报告的疾病负担很高,但患者群体管理不善且治疗不足。这表明宣传活动有助于提高患者对AD的认识,并促进早期诊断和获得专门的医疗机构服务。